- In April 2023, Oramed Pharmaceuticals Inc. announced positive top-line results from its Phase 2 clinical trial of ORMD-0801, its proprietary oral insulin candidate. The trial demonstrated meaningful reductions in fasting glucose and HbA1c levels among type 2 diabetes patients, showcasing the drug's potential as a non-invasive alternative to injectable insulin. This advancement reinforces Oramed’s commitment to transforming diabetes care through oral delivery of protein-based therapeutics and supports its continued leadership in this innovative segment
- In March 2023, Novo Nordisk reported expanded global availability of Rybelsus, the first oral GLP-1 receptor agonist for type 2 diabetes. Following regulatory approvals in Latin America and parts of Asia, the company increased its production capacity to meet growing global demand. This expansion illustrates Novo Nordisk’s strategic emphasis on accessibility and the scaling of oral peptide therapies to improve patient adherence and outcomes worldwide
- In March 2023, Rani Therapeutics unveiled advancements in its RaniPill platform, a robotic pill designed for oral delivery of biologics including peptides and antibodies. The company successfully completed a preclinical trial for octreotide, demonstrating controlled delivery and effective absorption. The development highlights Rani’s innovative approach to overcoming bioavailability challenges associated with oral protein administration and positions it at the forefront of next-generation drug delivery technologies
- In February 2023, Entera Bio Ltd. announced a research collaboration with a top-tier global pharmaceutical company to co-develop an oral parathyroid hormone (PTH) therapy for osteoporosis. The partnership leverages Entera’s proprietary technology platform for enhancing the bioavailability of large molecules via the oral route. This collaboration underscores the growing interest of major players in oral peptide development and reflects the therapeutic potential of such treatments for chronic bone-related conditions
- In January 2023, Protagonist Therapeutics achieved a clinical milestone with the initiation of a Phase 2 trial for PTG-300, an oral hepcidin mimetic targeting rare blood disorders such as polycythemia vera. This development represents a significant step in broadening the clinical utility of orally administered peptides in hematologic diseases and exemplifies the expanding scope of the oral peptide market beyond metabolic and gastrointestinal applications
